{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:00:40Z","timestamp":1776733240517,"version":"3.51.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the phase 3 EPOCH trial (Clinicaltrials.gov; NCT01739348), treatment with the BACE inhibitor verubecestat failed to improve cognition in patients with mild-to-moderate Alzheimer\u2019s disease, but was associated with reduced hippocampal volume after 78 weeks as assessed by MRI. The aims of the present exploratory analyses were to: (i) characterize the effect of verubecestat on brain volume by evaluating the time course of volumetric MRI changes for a variety of brain regions; and (ii) understand the mechanism through which verubecestat might cause hippocampal (and other brain region) volume loss by assessing its relationship to measures of amyloid, neurodegeneration, and cognition. Participants were aged 55\u201385 years with probable Alzheimer\u2019s disease dementia and a Mini Mental State Examination score \u226515 and \u226426. MRIs were obtained at baseline and at Weeks 13, 26, 52 and 78 of treatment. MRIs were segmented using Freesurfer and analysed using a tensor-based morphometry method. PET amyloid data were obtained with 18F-flutemetamol (Vizamyl\u00ae) at baseline and Week 78. Standardized uptake value ratios were generated with subcortical white matter as a reference region. Neurofilament light chain in the CSF was assessed as a biomarker of neurodegeneration. Compared with placebo, verubecestat showed increased MRI brain volume loss at Week 13 with no evidence of additional loss through Week 78. The verubecestat-related volumetric MRI loss occurred predominantly in amyloid-rich brain regions. Correlations between amyloid burden at baseline and verubecestat-related volumetric MRI reductions were not significant (r\u2009=\u20090.05 to 0.26, P-values &amp;gt; 0.27). There were no significant differences between verubecestat and placebo in changes from baseline in CSF levels of neurofilament light chain at Week 78 (increases of 7.2 and 14.6 pg\/ml for verubecestat versus 19.7 pg\/ml for placebo, P-values \u2265 0.1). There was a moderate correlation between volumetric MRI changes and cognitive decline in all groups including placebo at Week 78 (e.g. r = \u22120.45 to \u22120.55, P\u2009&amp;lt;\u20090.001 for whole brain), but the correlations were smaller at Week 13 and significant only for the verubecestat groups (e.g. r = \u22120.15 and \u22120.11, P\u2009&amp;lt;\u20090.04 for whole brain). Our results suggest that the verubecestat-associated MRI brain volume loss is not due to generalized, progressive neurodegeneration, but may be mediated by specific effects on BACE-related amyloid processes.<\/jats:p>","DOI":"10.1093\/brain\/awaa332","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T21:15:16Z","timestamp":1601414116000},"page":"3816-3826","source":"Crossref","is-referenced-by-count":69,"title":["BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer\u2019s disease brain"],"prefix":"10.1093","volume":"143","author":[{"given":"Cyrille","family":"Sur","sequence":"first","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Kost","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Scott","sequence":"additional","affiliation":[{"name":"Bioclinica, Newark, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Adamczuk","sequence":"additional","affiliation":[{"name":"Bioclinica, Newark, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick C","family":"Fox","sequence":"additional","affiliation":[{"name":"Institute of Neurology and UK Dementia Research Institute, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L","family":"Cummings","sequence":"additional","affiliation":[{"name":"University of Nevada Las Vegas (UNLV) School of Integrated Health Sciences, Las Vegas, NV, USA"},{"name":"UNLV Department of Brain Health, Las Vegas, NV, USA"},{"name":"UNLV, Chambers-Grundy Center for Transformative Neuroscience, Las Vegas, NV, USA"},{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre N","family":"Tariot","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, University of Arizona College of Medicine, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S","family":"Aisen","sequence":"additional","affiliation":[{"name":"University of Southern California, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[{"name":"Gerontopole, INSERM U 1027, Alzheimer\u2019s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffini","family":"Voss","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Mahoney","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Mukai","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew E","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Lines","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Michelson","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"Egan","sequence":"additional","affiliation":[{"name":"Merck and Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"2021092108142728000_OP-B1","year":"2000","edition":"4th"},{"key":"2021092108142728000_OP-B2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"key":"2021092108142728000_OP-B3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"key":"2021092108142728000_OP-B4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","article-title":"Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain","volume":"33","author":"Fischl","year":"2002","journal-title":"Neuron"},{"key":"2021092108142728000_OP-B5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cercor\/bhg087","article-title":"Automatically parcellating the human cerebral cortex","volume":"14","author":"Fischl","year":"2004","journal-title":"Cereb Cortex"},{"key":"2021092108142728000_OP-B6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"key":"2021092108142728000_OP-B7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"2021092108142728000_OP-B8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.24186","article-title":"Cerebrospinal fluid \u03b2-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease","volume":"76","author":"Fortea","year":"2014","journal-title":"Ann Neurol"},{"key":"2021092108142728000_OP-B9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"2021092108142728000_OP-B10","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1093\/brain\/awv283","article-title":"Different definitions of neurodegeneration produce similar amyloid\/neurodegeneration biomarker group findings","volume":"138","author":"Jack","year":"2015","journal-title":"Brain"},{"key":"2021092108142728000_OP-B11","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"2021092108142728000_OP-B12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mcn.2015.03.012","article-title":"Neurological consequences of traumatic brain injuries in sports","volume":"66 (Pt B","author":"Ling","year":"2015","journal-title":"Mol Cell Neurosci"},{"key":"2021092108142728000_OP-B13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2019.2214","article-title":"Staging \u03b2-amyloid pathology with amyloid Positron Emission Tomography","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"2021092108142728000_OP-B14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"2021092108142728000_OP-B15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3233\/JAD-150448","article-title":"Changes in brain volume with bapineuzumab in mild to moderate Alzheimer's disease","volume":"49","author":"Novak","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2021092108142728000_OP-B16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"2021092108142728000_OP-B17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jalz.2016.08.010","article-title":"Longitudinal brain structural changes in preclinical Alzheimer's disease","volume":"13","author":"Pegueroles","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2021092108142728000_OP-B18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"2021092108142728000_OP-B19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neuint.2007.05.007","article-title":"The functions of UCH-L1 and its relation to neurodegenerative diseases","volume":"51","author":"Setsuie","year":"2007","journal-title":"Neurochem Int"},{"key":"2021092108142728000_OP-B20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"2021092108142728000_OP-B21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"2021092108142728000_OP-B22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the beta secretase BACE1 for Alzheimer's disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol"},{"key":"2021092108142728000_OP-B23","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1523\/JNEUROSCI.4396-06.2007","article-title":"Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis","volume":"27","author":"Zhao","year":"2007","journal-title":"J Neurosci"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/12\/3816\/40418709\/awaa332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/12\/3816\/40418709\/awaa332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:19:25Z","timestamp":1632212365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/143\/12\/3816\/6012787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaa332","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,11,30]]}}}